MOTS-c vs AICAR

MOTS-c and AICAR are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

MOTS-c, or Mitochondrial Open Reading Frame of the 12S rRNA-c, is a 16-amino-acid peptide derived from the mitochondrial genome. Since its discovery by Lee et al. in 2015, it has been recognized for its role in metabolic regulation, primarily through the activation of AMP-activated protein kinase (AMPK). In preclinical studies involving mouse models, MOTS-c has demonstrated the ability to prevent diet-induced obesity and insulin resistance, notably increasing exercise capacity—older mice subjected to treadmill tests exhibited a doubling in endurance. Furthermore, research suggests that MOTS-c may mitigate age-related metabolic decline. Although a modified analog, CB4211, has shown promising tolerability in a Phase 1 human trial, there are currently no completed clinical trials assessing the effects of native MOTS-c in humans. The peptide is posited to enhance insulin sensitivity and glucose metabolism, alongside exercise mimetic and anti-obesity effects.

AICAR, or 5-aminoimidazole-4-carboxamide ribonucleoside, serves as a cell-permeable nucleoside analog that is phosphorylated to ZMP within cells, consequently activating AMPK. This activation mimics the metabolic adaptations typically induced by physical exercise, facilitating enhanced glucose uptake, fatty acid oxidation, and mitochondrial biogenesis, all while bypassing the need for muscular contraction. AICAR has been investigated in Phase II/III clinical trials, particularly focusing on its potential benefits in cardiac ischemia. However, it is important to note that AICAR is prohibited by the World Anti-Doping Agency (WADA) due to its classification as a metabolic modulator. The peptide is associated with significant metabolic effects, including improved insulin sensitivity and enhanced fatty acid oxidation, making it a subject of interest in various research contexts.

Both MOTS-c and AICAR are primarily studied for their roles in metabolic health, highlighting their potential to influence metabolic pathways and improve conditions related to metabolic dysfunction. Beyond this shared application, MOTS-c is also under investigation for its anti-aging properties, aiming to understand how it may alleviate age-related metabolic decline. In contrast, AICAR has been explored for its impact on body composition, particularly in the context of enhancing athletic performance and fat loss. The distinct yet overlapping research applications of these peptides underscore their relevance in the broader field of metabolic health and therapeutic development.

In terms of safety, MOTS-c has not been associated with adverse effects in preclinical animal studies, yet its human tolerability remains largely unknown due to the absence of completed clinical trials involving the native peptide. The modified analog CB4211, however, has demonstrated good tolerability in a Phase 1 study. Conversely, AICAR has been linked to transient hyperuricemia and mild hypoglycemia at elevated doses in clinical trials involving intravenous acadesine. There is a theoretical risk of lactic acidosis due to excessive AMPK activation, alongside potential hypoglycemia, particularly in fasted states or when combined with insulin. These safety profiles highlight the necessity for careful consideration in the context of research applications.